NCT05573698View on ClinicalTrials.gov

Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

August 25, 2023

Study Completion Date

August 25, 2023

Conditions
Friedreich Ataxia
Interventions
DRUG

DT-216

DT-216 will be administered by intravenous (IV) injection

DRUG

Placebo

Matching Placebo will be administered by intravenous (IV) injection

Trial Locations (1)

07724

Clinilabs, Eatontown

Sponsors
All Listed Sponsors
lead

Design Therapeutics, Inc.

INDUSTRY

NCT05573698 - Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia | Biotech Hunter | Biotech Hunter